FindTrial
Sign In

Paricalcitol Injection Long-term Safety Study

Paricalcitol Injection Long-term Safety Study

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220578
Enrollment
Unknown
Registered
2008-07-10
Start date
2008-07-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary Hyperparathyroidism

Interventions

investigational material(s) Generic name etc : ABT-358|Paricalcitol INN of investigational material : Paricalcitol Therapeutic category code : 311 Vitamin A, D and preparations Dosage and Administrati

Sponsors

Abbott Japan Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Aged 20 or over Subjects allocated to paricalcitol groups in the phase IIb study (dose-response study) and completed it with good tolerability to paricalcitol injection

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The proportion of subjects with iPTH measurement =<180 pg/mL at the final visit, etc.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026